arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Agios Pharmaceuticals, Inc.

AGIO Health Care Biotechnology: Pharmaceutical Preparations
$33.10
Today
as of Sep 4, 16:45 ET
Last 30 days -8.03% Jul 28 → Sep 04
$29.54 $31.27 $33.01 $34.74 $36.47 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$33.13
High
$33.50
Low
$32.92
Volume
$480,160
Avg Vol
$1M
Mkt Cap
$1.9B
P/E (TTM)
—
Beta
—
52w High
$46.00
52w Low
$22.24
Div Yield
—
Shares Out
$60M

Recent Press Releases & News last 60 days · 22 items

Jul 31 · 16:17 Zacks
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
Jul 30 · 19:02 GuruFocus.com
Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...
Jul 30 · 14:04 MarketBeat
Agios Pharmaceuticals Q2 Earnings Call Highlights
▸ Show all 22 press releases & news Free account →

Overview

52-week range
$22
$46
46% of range
Avg surprise (last 2)
+1.5%
Avg reaction (last 1)
+4.2%
100% positive
Latest IV / EM
66%
EM ±10.3% · $35 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.93$2.61$7.14$11.68$16.22 Actual $-1.47Actual $-1.51Actual $-1.64Actual $-1.45Actual $-1.69Actual $16.22Actual $-1.55Est $-1.80Actual $-1.93Est $-1.74Actual $-1.78Actual $-1.69Actual $-1.69 MarJunSepMarJunSepMar/2025Jun/2025SepMarJun
Revenue vs Net Income Revenue Net income
$-112M$165M$442M$718M$995M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.69 — — — — financials
Tue Mar 31, 2026Mar 2026 $-1.69 — — — — financials
Tue Sep 30, 2025Sep 2025 $-1.78 — — — — financials
Thu Jul 31, 2025Jun/2025 $-1.93 $-1.74 -10.9% — — earnings
Thu May 1, 2025Mar/2025 $-1.55 $-1.80 +13.9% — +4.2% earnings
Mon Sep 30, 2024Sep 2024 $16.22 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.69 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.45 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.64 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.51 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.47 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$45M$21M—$13M$12M$9M—$9M
Cost of revenue$3M$1M—$2M$2M$1M—$783,000
Gross profit————————
Operating income$-111M$-110M—$-117M$-127M$-107M—$-103M
Net income$-101M$-99M—$-103M$-112M$-89M—$948M
EPS (diluted)$-1.69$-1.69—$-1.78$-1.93$-1.55—$16.22

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$100M$114M$89M$93M$81M$79M$76M$254M
Inventory$36M$35M$33M$32M$31M$30M$28M$26M
Total current assets$718M$835M$942M$1.03B$1.02B$969M$966M$1.07B
Total assets$1.11B$1.18B$1.30B$1.39B$1.47B$1.56B$1.66B$1.79B
Long-term debt————————
Total liabilities$82M$76M$104M$101M$102M$89M$122M$165M
Total equity$1.03B$1.11B$1.19B$1.28B$1.37B$1.47B$1.54B$1.63B

Implied volatility — last 90 days

46%104%162%221%279% Jun 07 — IV 76% · EM ±10.5%Jun 08 — IV 105% · EM ±13.8%Jun 09 — IV 115% · EM ±14.4%Jun 10 — IV 95% · EM ±11.3%Jun 11 — IV 91% · EM ±10.0%Jun 12 — IV 86% · EM ±8.8%Jun 15 — IV 101% · EM ±7.3%Jun 16 — IV 279% · EM ±16.5%Jun 17 — IV 194% · EM ±8.1%Jun 19 — IV 60% · EM ±13.3%Jun 22 — IV 51% · EM ±10.7%Jun 23 — IV 72% · EM ±14.8%Jun 24 — IV 62% · EM ±12.4%Jun 25 — IV 72% · EM ±14.1%Jun 26 — IV 70% · EM ±13.4%Jun 29 — IV 66% · EM ±11.6%Jun 30 — IV 63% · EM ±10.8%Jul 01 — IV 82% · EM ±13.8%Jul 02 — IV 78% · EM ±12.6%Jul 03 — IV 81% · EM ±12.6%Jul 06 — IV 82% · EM ±11.4%Jul 07 — IV 87% · EM ±11.5%Jul 08 — IV 110% · EM ±13.8%Jul 09 — IV 115% · EM ±13.6%Jul 10 — IV 130% · EM ±14.3%Jul 13 — IV 80% · EM ±6.7%Jul 14 — IV 87% · EM ±6.3%Jul 15 — IV 158% · EM ±9.3%Jul 20 — IV 64% · EM ±15.0%Jul 21 — IV 82% · EM ±19.1%Jul 22 — IV 72% · EM ±16.4%Jul 23 — IV 67% · EM ±15.1%Jul 24 — IV 56% · EM ±12.4%Jul 27 — IV 76% · EM ±15.9%Jul 28 — IV 91% · EM ±18.6%Jul 29 — IV 57% · EM ±11.4%Jul 30 — IV 64% · EM ±12.4%Jul 31 — IV 87% · EM ±16.7%Aug 03 — IV 77% · EM ±13.6%Aug 04 — IV 87% · EM ±15.0%Aug 05 — IV 73% · EM ±12.1%Aug 06 — IV 119% · EM ±19.2%Aug 07 — IV 103% · EM ±16.1%Aug 10 — IV 82% · EM ±11.4%Aug 11 — IV 120% · EM ±15.9%Aug 12 — IV 85% · EM ±10.7%Aug 13 — IV 99% · EM ±11.7%Aug 14 — IV 67% · EM ±7.4%Aug 17 — IV 84% · EM ±7.0%Aug 18 — IV 132% · EM ±9.5%Aug 19 — IV 67% · EM ±4.0%Aug 20 — IV 271% · EM ±11.3%Aug 24 — IV 58% · EM ±12.1%Aug 25 — IV 67% · EM ±13.6%Aug 26 — IV 60% · EM ±12.0%Aug 27 — IV 47% · EM ±9.1%Aug 28 — IV 59% · EM ±11.3%Aug 31 — IV 47% · EM ±8.3%Sep 01 — IV 79% · EM ±13.5%Sep 02 — IV 65% · EM ±10.8%Sep 03 — IV 61% · EM ±9.8%Sep 04 — IV 66% · EM ±10.3%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in